January 20, 2017
Weil is advising Eli Lilly and Company, a global healthcare leader, in its $960 million acquisition of CoLucid Pharmaceuticals, Inc., a public biopharmaceutical company developing lasmiditan oral tablets for the acute treatment of migraine headaches. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline. The transaction is expected to close by the end of the first quarter of 2017 and is subject to customary closing conditions.
The Weil team advising Eli Lilly is led by Mergers & Acquisitions partners Raymond Gietz and Matthew Gilroy and includes Technology & IP Transactions partner Jeffrey Osterman; Tax partner Helyn Goldstein; Executive Compensation & Benefits partner Amy Rubin; Environmental counsel John O’Loughlin; Mergers & Acquisitions associates Christopher Moore, Christina De Vuono, Andrea Ryken and Stephen Liebscher (Not Yet Admitted in New York); Technology & IP Transactions associates Jennifer Yoon and Jasmine Woodard Rose; Tax associate Joseph Reich; Executive Compensation & Benefits associates Amanda Rosenblum and Franny Glick.